万泰生物上半年扣非亏2.4亿 2020年上市2募资共38.8亿

Core Viewpoint - Wantai Biological's financial performance in the first half of 2025 shows significant declines in revenue and profit, indicating potential challenges for the company moving forward [1]. Financial Performance Summary - In the first half of 2025, Wantai Biological achieved operating revenue of 844 million yuan, a decrease of 38.25% year-on-year [1][3]. - The net profit attributable to shareholders was -144 million yuan, down 155.30% from 260 million yuan in the same period last year [1][3]. - The net profit excluding non-recurring gains and losses was -243 million yuan, a decline of 481.93% compared to 63.5 million yuan in the previous year [1][3]. - The net cash flow from operating activities was -66.55 million yuan, compared to 129 million yuan in the same period last year, representing a decrease of 151.77% [1][3]. Previous Year Comparison - In 2024, Wantai Biological reported operating revenue of 2.245 billion yuan, a decline of 59.25% year-on-year [3]. - The net profit attributable to shareholders was 106 million yuan, down 91.49% from the previous year [3]. - The net profit excluding non-recurring gains and losses was -186 million yuan, compared to 1.078 billion yuan in the same period last year [3]. - The net cash flow from operating activities was 355 million yuan, a decrease of 76.91% year-on-year [3]. Company Background - Wantai Biological was listed on the Shanghai Stock Exchange on April 29, 2020, with an initial public offering of 43.6 million shares at a price of 8.75 yuan per share [4]. - The total funds raised in the IPO amounted to 382 million yuan, with a net amount of 318 million yuan after expenses [4]. - The company has utilized the raised funds for various projects, including automation technology upgrades and international certification for its products [4].